Charles Schwab Investment Management Inc. Has $2.80 Million Stock Position in argenex SE $ARGX

Key Points

• Charles Schwab Investment Management Inc. increased its stake in argenex SE by 12.3%, bringing its holdings to a value of $2.80 million after acquiring an additional 518 shares.
• Institutional investors and hedge funds collectively own 60.32% of argenex's stock, indicating substantial institutional interest in the company.
• Recent analyst forecasts for argenex show a consensus rating of "Buy" with a price target averaging around $766.50, reflecting positive expectations for the company's performance.

Charles Schwab Investment Management Inc. grew its holdings in argenex SE (NASDAQ:ARGX - Free Report) by 12.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,732 shares of the company's stock after acquiring an additional 518 shares during the quarter. Charles Schwab Investment Management Inc.'s holdings in argenex were worth $2,801,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Point72 Asset Management L.P. acquired a new stake in shares of argenex in the fourth quarter valued at approximately $91,013,000. GAMMA Investing LLC increased its stake in argenex by 53,684.9% during the 1st quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock worth $802,200,000 after acquiring an additional 135,286 shares during the period. Assenagon Asset Management S.A. raised its holdings in argenex by 215.8% in the 1st quarter. Assenagon Asset Management S.A. now owns 110,390 shares of the company's stock valued at $65,336,000 after acquiring an additional 75,435 shares in the last quarter. Lazard Asset Management LLC lifted its position in shares of argenex by 1,086.6% during the 4th quarter. Lazard Asset Management LLC now owns 70,637 shares of the company's stock valued at $43,440,000 after acquiring an additional 64,684 shares during the period. Finally, Woodline Partners LP lifted its position in shares of argenex by 299.5% during the 4th quarter. Woodline Partners LP now owns 74,237 shares of the company's stock valued at $45,656,000 after acquiring an additional 55,656 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Stock Up 1.6%

Shares of NASDAQ:ARGX traded up $11.65 during trading on Thursday, hitting $733.66. 544,073 shares of the company were exchanged, compared to its average volume of 354,959. argenex SE has a 1-year low of $510.05 and a 1-year high of $742.52. The company has a market capitalization of $44.90 billion, a P/E ratio of 37.62, a price-to-earnings-growth ratio of 0.76 and a beta of 0.41. The business's 50 day moving average is $624.07 and its 200-day moving average is $601.86.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.90. argenex had a return on equity of 21.06% and a net margin of 40.98%.The company had revenue of $866.79 million for the quarter, compared to the consensus estimate of $776.82 million. As a group, sell-side analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Guggenheim raised their price target on argenex from $1,060.00 to $1,070.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. JPMorgan Chase & Co. raised their target price on shares of argenex from $775.00 to $830.00 and gave the company an "overweight" rating in a report on Monday, August 4th. Bank of America boosted their target price on shares of argenex from $880.00 to $887.00 and gave the company a "buy" rating in a research report on Tuesday. Royal Bank Of Canada began coverage on shares of argenex in a report on Monday, August 25th. They set an "outperform" rating and a $850.00 price target for the company. Finally, JMP Securities set a $699.00 price objective on shares of argenex in a research note on Wednesday, May 14th. Two investment analysts have rated the stock with a Strong Buy rating and twenty-one have assigned a Buy rating to the company. According to MarketBeat.com, argenex currently has an average rating of "Buy" and a consensus price target of $772.84.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.